Aclidinium bromide/formoterol fumarate vs Tiotropium bromide
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Chronic Obstructive Pulmonary Disease
Shared mechanism: Muscarinic acetylcholine receptor (M3) · full Chronic Obstructive Pulmonary Disease pipeline
Aclidinium bromide/formoterol fumarate · Duaklir Pressair
Rights held by Azurity Pharmaceuticals and partners; US product discontinued
NCT01437397 · Phase 3 · completed
This was a large randomized, quadruple-blind, placebo- and active-controlled trial with 1,692 randomized participants, using the regulator-accepted clinical lung-function measure FEV1 as its primary endpoint. Results were mixed: the 400/12 μg combination significantly improved post-dose FEV1 versus aclidinium and trough FEV1 versus formoterol, whereas the 400/6 μg combination did not significantly improve trough FEV1 versus formoterol (p=0.133).
Reported efficacy
Change From Baseline in 1-hour Morning Post Forced Expiratory Volume in 1 Second (FEV1) (Week 24, 1-hour morning post-dose); Change From Baseline in Morning Pre-dose (Trough) FEV1 for Aclidinium Bromide/Formoterol Fumarate (Week 24, morning pre-dose (trough)); Change From Baseline in Morning Pre-dose (Trough) FEV1 for Aclidinium Bromide (Week 24, morning pre-dose (trough)): Change From Baseline in 1-hour Morning Post Forced Expiratory Volume in 1 Second (FEV1) (Week 24, 1-hour morning post-dose): AB/FF 400/12 μg 0.248 Litres (Standard Error 0.013) vs AB 400 μg 0.156 Litres (Standard Error 0.013) | FF 12 μg 0.138 Litres (Standard Error 0.013) | Placebo -0.05 Litres (Standard Error 0.013) (met)
Result source: NCT03022097
Tiotropium bromide
Marketed by Boehringer Ingelheim
NCT02172287 · Phase 3 · completed
This 6-month trial randomly assigned 623 patients with COPD to tiotropium, salmeterol or placebo, with double-blind, double-dummy treatment. The two primary measures were trough FEV1 and the Transition Dyspnea Index (TDI). Tiotropium raised trough FEV1 by 0.14 L more than placebo, more than salmeterol did (0.09 L; p<0.01 for tiotropium against salmeterol), and improved the TDI focal score by 1.02 units against placebo (p=0.01). Both primary measures favoured tiotropium, so the result is met. The figures come from the peer-reviewed paper in Chest (2002).
Reported efficacy
Change from baseline in trough Forced expiratory volume in one second (FEV1) response (baseline, up to day 169); Change from baseline in Mahler Transitional Dyspnoea Index (TDI) (baseline, up to day 169): Primary 1, trough (predose morning) FEV1 change at 6 months vs placebo: tiotropium +0.14 L, salmeterol +0.09 L (tiotropium vs salmeterol p<0.01), met. Primary 2, TDI focal score at 6 months: tiotropium +1.02 units vs placebo (p=0.01), met; salmeterol +0.24 units, not significant. (met)
Result source: NCT02172287
Results for Chronic Obstructive Pulmonary Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Aclidinium bromide/formoterol fumarate | Tiotropium bromide |
|---|---|---|
| Moderate or severe exacerbations, annualised rate | —Not reported | 0.9 vs 1.3−0.4 vs placeboNCT016639871 other result
|
| Trough FEV1, change | 0.1 vs -0.0+0.1 vs placeboNCT014373975 other results
| 0.1 vs 0.1vs ABNCT0279667742 other results
|
| SGRQ total, change | -6.6 vs -2.2−4.4 vs placeboNCT014373974 other results
| -4.1 vs -2.0−2.1 vs placeboNCT00496470 |
| TDI focal score | 2.0 vs 0.6+1.4 vs placeboNCT014373975 other results
| —Not posted · NCT02172287 |
Moderate or severe exacerbations, annualised rate
- Aclidinium bromide/formoterol fumarate
- —Not reported
- Tiotropium bromide
- 0.9 vs 1.3−0.4 vs placeboNCT01663987
1 other result
- 0.9 vs 1.3 NCT01662986
Trough FEV1, change
- Aclidinium bromide/formoterol fumarate
- 0.1 vs -0.0+0.1 vs placeboNCT01437397
5 other results
- 0.1 vs -0.0 NCT01437397
- 0.1 vs -0.1 NCT01462942
- 0.1 vs -0.1 NCT01462942
- 0.1 vs -0.1 NCT03022097
- 0.1 vs -0.1 NCT03022097
- Tiotropium bromide
- 0.1 vs 0.1vs ABNCT02796677
42 other results
- 0.2 vs -0.1 NCT01663987
- 0.2 vs 0.1 NCT01662986
- 0.1 vs 0.1 NCT03118765
- 0.1 vs 0.1 NCT03118765
- 0.1 vs 0.1 NCT03118765
- 0.2 vs 0.1 NCT00696020
- 0.1 vs 0.1 NCT00696020
- 0.1 vs 0.1 NCT00696020
- 0.1 vs -0.0 NCT00359788
- 0.1 vs -0.0 NCT00528996
- 0.1 vs -0.0 NCT00528996
- 0.1 vs -0.0 NCT00528996
- 0.1 vs -0.0 NCT00528996
- 0.1 vs -0.0 NCT00528996
- 0.1 vs -0.0 NCT00528996
- 0.1 vs -0.0 NCT00528996
- 0.1 vs -0.0 NCT00528996
- 0.1 vs -0.0 NCT00528996
- 0.1 vs -0.0 NCT00528996
- 0.1 vs -0.0 NCT00528996
- 0.1 vs -0.0 NCT00528996
- 0.1 vs -0.0 NCT00528996
- 0.1 vs -0.0 NCT00528996
- 0.1 vs -0.0 NCT00528996
- 0.1 vs -0.0 NCT00528996
- 0.1 vs -0.0 NCT00528996
- 0.1 vs -0.0 NCT00528996
- 0.1 vs -0.1 NCT00523991
- 0.1 vs -0.1 NCT00523991
- 0.1 vs -0.1 NCT00523991
- 0.1 vs -0.1 NCT00523991
- 0.1 vs -0.0 NCT00523991
- 0.1 vs -0.0 NCT00523991
- 0.2 vs 0.0 NCT01663987
- 0.2 vs 0.0 NCT01662986
- 0.1 vs 0.0 NCT00528996
- 0.1 vs 0.0 NCT00528996
- 0.1 vs 0.0 NCT00528996
- 0.1 vs 0.0 NCT00528996
- 0.0 vs 0.0 NCT00528996
- 0.1 vs 0.0 NCT00528996
- 0.1 vs -0.0 NCT00359788
SGRQ total, change
- Aclidinium bromide/formoterol fumarate
- -6.6 vs -2.2−4.4 vs placeboNCT01437397
4 other results
- -5.9 vs -2.2 NCT01437397
- -7.2 vs -6.5 NCT01462942
- -8.3 vs -6.5 NCT01462942
- -8.7 vs -4.7 NCT03022097
- Tiotropium bromide
- -4.1 vs -2.0−2.1 vs placeboNCT00496470
TDI focal score
- Aclidinium bromide/formoterol fumarate
- 2.0 vs 0.6+1.4 vs placeboNCT01437397
5 other results
- 2.0 vs 0.6 NCT01437397
- 2.5 vs 1.2 NCT01462942
- 2.4 vs 1.2 NCT01462942
- 2.9 vs 2.1 NCT03022097
- 1.9 vs 1.9 NCT01908140
- Tiotropium bromide
- —Not posted · NCT02172287
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
2 other shared endpoints and safety
Coverage. Aclidinium bromide/formoterol fumarate: 6 of 6 rows · Tiotropium bromide: 6 of 6 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Aclidinium bromide/formoterol fumarate Rows use multiple source trials | Tiotropium bromide Rows use multiple source trials |
|---|---|---|
| FEV1 Change 1h absolute change · L | 0.247 vs -0.037 placebo L @ 24wk400/12 μga,b,c NCT01437397 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3 show 1 more dose0.226 vs -0.037 placebo L @ 24wk400/6 μg NCT01437397 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3 | 0.253 vs 0.169 AB L @ 24wk400/12 μgb,c NCT02796677 · Phase 3 · registry result, not featured evidence |
| FEV1 Peak absolute change · L | 0.324 vs 0.008 placebo L @ 24wk400/12 μgd,b,c NCT03022097 · Phase 3 · combination · Chronic Obstructive Pulmonary Disease · phase 3 1 other source trial1.655 vs 1.562 Salmeterol / Fluticasone L @ 24wk NCT01908140 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3 | 0.26 vs 0.02 placebo L @ 24wkd,b,c NCT00523991 · Phase 4 · registry result, not featured evidence 3 other source trials0.216 vs 0.051 placebo L @ 24wk100 mcg NCT00528996 · Phase 2 · registry result, not featured evidence 0.216 vs 0.051 placebo L @ 24wk200 mcg NCT00528996 · Phase 2 · registry result, not featured evidence 0.207 vs 0.051 placebo L @ 24wk50 mcg NCT00528996 · Phase 2 · registry result, not featured evidence |
| Dropout rate | 19.5%400/12 μge NCT01437397 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3 show 7 more results18.3%400/6 μg NCT01437397 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3 7.9%400/12 μg NCT03022097 · Phase 3 · combination · Chronic Obstructive Pulmonary Disease · phase 3 14.1% NCT01908140 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3 8.8%400/12 μg NCT01462942 · Phase 3 10.5%400/6 μg NCT01462942 · Phase 3 32.4%400 μg/12 μg NCT01437540 · Phase 3 · registry result, not featured evidence 5%400/12 BID NCT03276078 · Phase 2 · registry result, not featured evidence | 10.3%50/250 µg BIDf NCT01762800 · Phase 4 · registry result, not featured evidence show 37 more results—50/250 µg BID NCT01762800 · Phase 4 · registry result, not featured evidence —50/250 µg BID + 18 µg QD NCT01762800 · Phase 4 · registry result, not featured evidence · combination —18 µg QD + 50/250 µg BID NCT01762800 · Phase 4 · registry result, not featured evidence · combination 15%18μg NCT01663987 · Phase 4 · registry result, not featured evidence 33.3%18 μg NCT01662986 · Phase 4 · registry result, not featured evidence —50/250 µg BID NCT01751113 · Phase 4 · registry result, not featured evidence —50/250 µg BID + 18 µg QD NCT01751113 · Phase 4 · registry result, not featured evidence · combination 11.3% NCT00523991 · Phase 4 · registry result, not featured evidence 7.9% NCT00496470 · Phase 4 · registry result, not featured evidence · combination 13.3% NCT00359788 · Phase 4 · registry result, not featured evidence — NCT03137992 · Phase 3 · registry result, not featured evidence —5 mcg NCT02683668 · Phase 3 · registry result, not featured evidence —18 mcg NCT02683668 · Phase 3 · registry result, not featured evidence 0%18 mcg NCT02683668 · Phase 3 · registry result, not featured evidence —400/12 μg NCT02796677 · Phase 3 · registry result, not featured evidence 23.2%5 mcg NCT01126437 · Phase 3 · registry result, not featured evidence 23%18 mcg NCT01126437 · Phase 3 · registry result, not featured evidence 23.4%2.5 mcg NCT01126437 · Phase 3 · registry result, not featured evidence —150 μg NCT00999908 · Phase 3 · registry result, not featured evidence 13.3%10 μg NCT03118765 · Phase 2 · registry result, not featured evidence 16.1%40 μg NCT03118765 · Phase 2 · registry result, not featured evidence 6.3%20 μg NCT03118765 · Phase 2 · registry result, not featured evidence —5 mcg NCT01222533 · Phase 2 · registry result, not featured evidence —18 mcg NCT01222533 · Phase 2 · registry result, not featured evidence —2.5 mcg NCT01222533 · Phase 2 · registry result, not featured evidence —1.25 mcg NCT01222533 · Phase 2 · registry result, not featured evidence —5 mcg NCT01040403 · Phase 2 · registry result, not featured evidence —10 mcg NCT01040403 · Phase 2 · registry result, not featured evidence —tiotropium 5 mcg + olodaterol 10 mcg NCT01040403 · Phase 2 · registry result, not featured evidence · combination —tiotropium 5 mcg + olodaterol 5 mcg NCT01040403 · Phase 2 · registry result, not featured evidence · combination —tiotropium 2.5 mcg + olodaterol 10 mcg NCT01040403 · Phase 2 · registry result, not featured evidence · combination —tiotropium 2.5 mcg + olodaterol 5 mcg NCT01040403 · Phase 2 · registry result, not featured evidence · combination —tiotropium 1.25 mcg + olodaterol 10 mcg NCT01040403 · Phase 2 · registry result, not featured evidence · combination —tiotropium 1.25 mcg + olodaterol 5 mcg NCT01040403 · Phase 2 · registry result, not featured evidence · combination 4.5%5/10 μg NCT00696020 · Phase 2 · registry result, not featured evidence · combination 2.2%5/2 μg NCT00696020 · Phase 2 · registry result, not featured evidence · combination 3.2%5/5 μg NCT00696020 · Phase 2 · registry result, not featured evidence · combination |
| Discontinued due to AEs | 6.2%400/12 μge NCT01437397 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3 show 7 more results6.5%400/6 μg NCT01437397 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3 1.1%400/12 μg NCT03022097 · Phase 3 · combination · Chronic Obstructive Pulmonary Disease · phase 3 4.7% NCT01908140 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3 3.1%400/12 μg NCT01462942 · Phase 3 2.6%400/6 μg NCT01462942 · Phase 3 6.6%400 μg/12 μg NCT01437540 · Phase 3 · registry result, not featured evidence 5%400/12 BID NCT03276078 · Phase 2 · registry result, not featured evidence | 6.4%50/250 µg BIDf NCT01762800 · Phase 4 · registry result, not featured evidence show 37 more results—50/250 µg BID NCT01762800 · Phase 4 · registry result, not featured evidence —50/250 µg BID + 18 µg QD NCT01762800 · Phase 4 · registry result, not featured evidence · combination —18 µg QD + 50/250 µg BID NCT01762800 · Phase 4 · registry result, not featured evidence · combination 5%18μg NCT01663987 · Phase 4 · registry result, not featured evidence 10.3%18 μg NCT01662986 · Phase 4 · registry result, not featured evidence —50/250 µg BID NCT01751113 · Phase 4 · registry result, not featured evidence —50/250 µg BID + 18 µg QD NCT01751113 · Phase 4 · registry result, not featured evidence · combination 2.1% NCT00523991 · Phase 4 · registry result, not featured evidence 2.4% NCT00496470 · Phase 4 · registry result, not featured evidence · combination 6.4% NCT00359788 · Phase 4 · registry result, not featured evidence — NCT03137992 · Phase 3 · registry result, not featured evidence —5 mcg NCT02683668 · Phase 3 · registry result, not featured evidence —18 mcg NCT02683668 · Phase 3 · registry result, not featured evidence —18 mcg NCT02683668 · Phase 3 · registry result, not featured evidence —400/12 μg NCT02796677 · Phase 3 · registry result, not featured evidence 10.6%5 mcg NCT01126437 · Phase 3 · registry result, not featured evidence 11.1%18 mcg NCT01126437 · Phase 3 · registry result, not featured evidence 10.5%2.5 mcg NCT01126437 · Phase 3 · registry result, not featured evidence —150 μg NCT00999908 · Phase 3 · registry result, not featured evidence 3.3%10 μg NCT03118765 · Phase 2 · registry result, not featured evidence 3.2%40 μg NCT03118765 · Phase 2 · registry result, not featured evidence 3.1%20 μg NCT03118765 · Phase 2 · registry result, not featured evidence —5 mcg NCT01222533 · Phase 2 · registry result, not featured evidence —18 mcg NCT01222533 · Phase 2 · registry result, not featured evidence —2.5 mcg NCT01222533 · Phase 2 · registry result, not featured evidence —1.25 mcg NCT01222533 · Phase 2 · registry result, not featured evidence —5 mcg NCT01040403 · Phase 2 · registry result, not featured evidence —10 mcg NCT01040403 · Phase 2 · registry result, not featured evidence —tiotropium 5 mcg + olodaterol 10 mcg NCT01040403 · Phase 2 · registry result, not featured evidence · combination —tiotropium 5 mcg + olodaterol 5 mcg NCT01040403 · Phase 2 · registry result, not featured evidence · combination —tiotropium 2.5 mcg + olodaterol 10 mcg NCT01040403 · Phase 2 · registry result, not featured evidence · combination —tiotropium 2.5 mcg + olodaterol 5 mcg NCT01040403 · Phase 2 · registry result, not featured evidence · combination —tiotropium 1.25 mcg + olodaterol 10 mcg NCT01040403 · Phase 2 · registry result, not featured evidence · combination —tiotropium 1.25 mcg + olodaterol 5 mcg NCT01040403 · Phase 2 · registry result, not featured evidence · combination 1.1%5/10 μg NCT00696020 · Phase 2 · registry result, not featured evidence · combination 1.1%5/2 μg NCT00696020 · Phase 2 · registry result, not featured evidence · combination 2.2%5/5 μg NCT00696020 · Phase 2 · registry result, not featured evidence · combination |
| Serious AEs | 5.7%400/12 μge NCT01437397 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3 show 7 more results5.4%400/6 μg NCT01437397 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3 7.2%400/12 μg NCT03022097 · Phase 3 · combination · Chronic Obstructive Pulmonary Disease · phase 3 7.5% NCT01908140 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3 6%400/12 μg NCT01462942 · Phase 3 4.7%400/6 μg NCT01462942 · Phase 3 9.7%400 μg/12 μg NCT01437540 · Phase 3 · registry result, not featured evidence 5%400/12 BID NCT03276078 · Phase 2 · registry result, not featured evidence | —50/250 µg BIDf NCT01762800 · Phase 4 · registry result, not featured evidence show 37 more results5.9%50/250 µg BID NCT01762800 · Phase 4 · registry result, not featured evidence 8.8%50/250 µg BID + 18 µg QD NCT01762800 · Phase 4 · registry result, not featured evidence · combination 10.7%18 µg QD + 50/250 µg BID NCT01762800 · Phase 4 · registry result, not featured evidence · combination 37.5%18μg NCT01663987 · Phase 4 · registry result, not featured evidence 25.6%18 μg NCT01662986 · Phase 4 · registry result, not featured evidence 0%50/250 µg BID NCT01751113 · Phase 4 · registry result, not featured evidence 3.8%50/250 µg BID + 18 µg QD NCT01751113 · Phase 4 · registry result, not featured evidence · combination 4.2% NCT00523991 · Phase 4 · registry result, not featured evidence 3% NCT00496470 · Phase 4 · registry result, not featured evidence · combination 6.4% NCT00359788 · Phase 4 · registry result, not featured evidence 0% NCT03137992 · Phase 3 · registry result, not featured evidence —5 mcg NCT02683668 · Phase 3 · registry result, not featured evidence —18 mcg NCT02683668 · Phase 3 · registry result, not featured evidence —18 mcg NCT02683668 · Phase 3 · registry result, not featured evidence 7.3%400/12 μg NCT02796677 · Phase 3 · registry result, not featured evidence 32.9%5 mcg NCT01126437 · Phase 3 · registry result, not featured evidence 33.9%18 mcg NCT01126437 · Phase 3 · registry result, not featured evidence 33.8%2.5 mcg NCT01126437 · Phase 3 · registry result, not featured evidence 0%150 μg NCT00999908 · Phase 3 · registry result, not featured evidence 0%10 μg NCT03118765 · Phase 2 · registry result, not featured evidence 0%40 μg NCT03118765 · Phase 2 · registry result, not featured evidence 0%20 μg NCT03118765 · Phase 2 · registry result, not featured evidence 2%5 mcg NCT01222533 · Phase 2 · registry result, not featured evidence 1.4%18 mcg NCT01222533 · Phase 2 · registry result, not featured evidence 0%2.5 mcg NCT01222533 · Phase 2 · registry result, not featured evidence 1.4%1.25 mcg NCT01222533 · Phase 2 · registry result, not featured evidence 3.7%5 mcg NCT01040403 · Phase 2 · registry result, not featured evidence 1.8%10 mcg NCT01040403 · Phase 2 · registry result, not featured evidence 0%tiotropium 5 mcg + olodaterol 10 mcg NCT01040403 · Phase 2 · registry result, not featured evidence · combination 0.9%tiotropium 5 mcg + olodaterol 5 mcg NCT01040403 · Phase 2 · registry result, not featured evidence · combination 4.5%tiotropium 2.5 mcg + olodaterol 10 mcg NCT01040403 · Phase 2 · registry result, not featured evidence · combination 2.7%tiotropium 2.5 mcg + olodaterol 5 mcg NCT01040403 · Phase 2 · registry result, not featured evidence · combination 0.9%tiotropium 1.25 mcg + olodaterol 10 mcg NCT01040403 · Phase 2 · registry result, not featured evidence · combination 0.9%tiotropium 1.25 mcg + olodaterol 5 mcg NCT01040403 · Phase 2 · registry result, not featured evidence · combination 0%5/10 μg NCT00696020 · Phase 2 · registry result, not featured evidence · combination 3.4%5/2 μg NCT00696020 · Phase 2 · registry result, not featured evidence · combination 1.1%5/5 μg NCT00696020 · Phase 2 · registry result, not featured evidence · combination |
| Most frequent reported AEs | 400/12 μge chronic obstructive pulmonary disease 15.2% (placebo 17.5%) cough 5.1% (placebo 3.6%) nasopharyngitis 4.8% (placebo 3.6%) NCT01437397 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3 show 7 more results400/6 μg chronic obstructive pulmonary disease 14.7% (placebo 17.5%) nasopharyngitis 5.1% (placebo 3.6%) cough 3.9% (placebo 3.6%) NCT01437397 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3 400/12 μg upper respiratory tract infection 11.8% (placebo 8.9%) chronic obstructive pulmonary disease 9.5% (placebo 13%) NCT03022097 · Phase 3 · combination · Chronic Obstructive Pulmonary Disease · phase 3 chronic obstructive pulmonary disease 15% headache 6% nasopharyngitis 5.6% NCT01908140 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3 400/12 μg chronic obstructive pulmonary disease 8.6% (placebo 11.9%) nasopharyngitis 7.8% (placebo 7.2%) headache 7.5% (placebo 8.2%) NCT01462942 · Phase 3 400/6 μg chronic obstructive pulmonary disease 9.4% (placebo 11.9%) nasopharyngitis 7.9% (placebo 7.2%) headache 7.1% (placebo 8.2%) NCT01462942 · Phase 3 400 μg/12 μg chronic obstructive pulmonary disease 27% urinary tract infection 6.6% nasopharyngitis 6.4% NCT01437540 · Phase 3 · registry result, not featured evidence | 50/250 µg BIDf nasopharyngitis 18.4% dysphonia 13.2% bronchitis 5.1% NCT01762800 · Phase 4 · registry result, not featured evidence show 27 more results50/250 µg BID + 18 µg QD nasopharyngitis 20.6% bronchitis 10.3% dysphonia 8.8% NCT01762800 · Phase 4 · registry result, not featured evidence · combination 18 µg QD + 50/250 µg BID nasopharyngitis 26.7% dysphonia 8% bronchitis 6.7% NCT01762800 · Phase 4 · registry result, not featured evidence · combination 18μg chronic obstructive pulmonary disease 37.5% (placebo 43.6%) bronchitis 7.5% (placebo 5.1%) insomnia 5% (placebo 5.1%) NCT01663987 · Phase 4 · registry result, not featured evidence 18 μg chronic obstructive pulmonary disease 25.6% (placebo 15.4%) contusion 7.7% (placebo 0%) oedema peripheral 7.7% (placebo 0%) NCT01662986 · Phase 4 · registry result, not featured evidence 50/250 µg BID dysphonia 5.9% constipation 2% dry mouth 2% NCT01751113 · Phase 4 · registry result, not featured evidence 50/250 µg BID + 18 µg QD dysphonia 9.6% nasopharyngitis 5.8% arthralgia 3.8% NCT01751113 · Phase 4 · registry result, not featured evidence · combination nasophayngitis 6.7% (placebo 5%) chronic obstructive pulmonary disease 4.6% (placebo 9.6%) NCT00523991 · Phase 4 · registry result, not featured evidence chronic obstructive pulmonary disease 6.4% NCT00359788 · Phase 4 · registry result, not featured evidence 400/12 μg chronic obstructive pulmonary 15.6% nasopharyngitis 11.5% headache 5.1% NCT02796677 · Phase 3 · registry result, not featured evidence 5 mcg chronic obstructive pulmonary disease 32.9% NCT01126437 · Phase 3 · registry result, not featured evidence 18 mcg chronic obstructive pulmonary disease 33.9% NCT01126437 · Phase 3 · registry result, not featured evidence 2.5 mcg chronic obstructive pulmonary disease 33.8% NCT01126437 · Phase 3 · registry result, not featured evidence 10 μg cough 3.3% (placebo 0%) headache 3.3% (placebo 3%) urinary tract infection 3.3% (placebo 3%) NCT03118765 · Phase 2 · registry result, not featured evidence 40 μg dry mouth 12.9% (placebo 0%) dizziness 3.2% (placebo 6.1%) back pain 0% (placebo 3%) NCT03118765 · Phase 2 · registry result, not featured evidence 20 μg back pain 6.3% (placebo 3%) headache 6.3% (placebo 3%) cough 3.1% (placebo 0%) NCT03118765 · Phase 2 · registry result, not featured evidence 5 mcg nasopharyngitis 9.3% (placebo 4.1%) dyspnoea 2% (placebo 9.5%) NCT01222533 · Phase 2 · registry result, not featured evidence 18 mcg nasopharyngitis 4.8% (placebo 4.1%) dyspnoea 2.1% (placebo 9.5%) NCT01222533 · Phase 2 · registry result, not featured evidence 2.5 mcg dyspnoea 1.4% (placebo 9.5%) nasopharyngitis 1.4% (placebo 4.1%) NCT01222533 · Phase 2 · registry result, not featured evidence 1.25 mcg nasopharyngitis 6.1% (placebo 4.1%) dyspnoea 3.4% (placebo 9.5%) NCT01222533 · Phase 2 · registry result, not featured evidence 5 mcg nasopharyngitis 10.2% chronic obstructive pulmonary disease 5.6% NCT01040403 · Phase 2 · registry result, not featured evidence 10 mcg nasopharyngitis 6.4% chronic obstructive pulmonary disease 5.5% NCT01040403 · Phase 2 · registry result, not featured evidence tiotropium 5 mcg + olodaterol 10 mcg chronic obstructive pulmonary disease 3.6% nasopharyngitis 1.8% NCT01040403 · Phase 2 · registry result, not featured evidence · combination tiotropium 5 mcg + olodaterol 5 mcg chronic obstructive pulmonary disease 7.3% nasopharyngitis 2.8% NCT01040403 · Phase 2 · registry result, not featured evidence · combination tiotropium 2.5 mcg + olodaterol 10 mcg nasopharyngitis 3.6% chronic obstructive pulmonary disease 2.7% NCT01040403 · Phase 2 · registry result, not featured evidence · combination tiotropium 2.5 mcg + olodaterol 5 mcg nasopharyngitis 7.1% chronic obstructive pulmonary disease 2.7% NCT01040403 · Phase 2 · registry result, not featured evidence · combination tiotropium 1.25 mcg + olodaterol 10 mcg nasopharyngitis 7.3% chronic obstructive pulmonary disease 6.4% NCT01040403 · Phase 2 · registry result, not featured evidence · combination tiotropium 1.25 mcg + olodaterol 5 mcg nasopharyngitis 11% chronic obstructive pulmonary disease 3.7% NCT01040403 · Phase 2 · registry result, not featured evidence · combination |
Notes
- aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- bPopulation comparability has not been reviewed for both studies.
- cTreatment context has not been resolved for both arms.
- dTrial phases differ: Phase 4 versus Phase 3.
- ePopulation comparability has not been reviewed for 4 of these studies.
- fPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Aclidinium bromide/formoterol fumarate
show 5 more results
Tiotropium bromide
show 5 more results
show 2 more results
show 2 more results
show 2 more results
show 2 more results
show 2 more results
show 2 more results
show 2 more results
show 2 more results
show 2 more results
show 2 more results
show 2 more results
+ 112 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Aclidinium bromide/formoterol fumarate's landscape · Tiotropium bromide's landscape